GTHX
G1 Therapeutics Inc
Halal Rating :
Last Price
$7.16
Last updated:
Market Cap
-
7D Change
0.07%
1 Year Change
467.86%
Company Overview
Industries
Exchange
Next Earnings Date
G1 Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with cancer. Their lead product COSELA™ (trilaciclib) is the first and only therapy approved by the FDA to help protect bone marrow when administered prior to chemotherapy.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $16.55m | $22.81m | - | $2.73m | 0.00% | 11.95% |
| March 31, 2024 | $14.48m | $25.5m | - | $1.98m | 0.00% | 7.76% |
| Dec. 31, 2023 | $14.87m | $33.12m | - | $2.12m | 0.00% | 6.41% |
Company Impact
Help us evaluate G1 Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.